Circulating endothelial microparticles and miR-92a in acute myocardial infarction

Area of Science:

• Cardiovascular Research
• Biomarker Discovery
• Endothelial Dysfunction

Background:

• Coronary artery disease (CAD) involves endothelial dysfunction.
• Microparticles (MPs) and microRNAs (miRNAs) are implicated in CAD pathogenesis.
• Endothelial MPs (EMPs) and specific miRNAs may serve as diagnostic markers.

Purpose of the Study:

• To evaluate the diagnostic utility of EMPs (CD31+/CD42b-) and miRNAs (miR-92a, miR-23a) in differentiating acute myocardial infarction (AMI) from stable CAD (SCAD).
• To explore the correlation between EMPs and miRNA levels in AMI patients.
• To assess the potential of these biomarkers in monitoring endothelial dysfunction in AMI.

Main Methods:

• Plasma samples analyzed from 37 AMI patients, 42 SCAD patients, and 35 healthy controls.
• Quantification of specific MP populations (CD31+/CD42b-, CD31+/CD42b+, CD31-/CD42b-) using flow cytometry.
• Measurement of miR-92a and miR-23a levels via reverse transcription-quantitative PCR.
• Cardiac troponin I (cTnI) measured by ELISA as a standard diagnostic parameter.

Main Results:

• CD31+/CD42b- MP levels were significantly higher in the AMI group compared to SCAD and healthy groups.
• miR-92a expression was significantly elevated in AMI patients relative to both SCAD and healthy groups.
• A positive correlation was observed between CD31+/CD42b- MP levels and miR-92a expression.
• Receiver operating characteristic (ROC) curve analysis showed high diagnostic accuracy for CD31+/CD42b- MPs (AUC=0.893), miR-92a (AUC=0.888), and cTnI (AUC=0.912).

Conclusions:

• CD31+/CD42b- EMPs and miR-92a demonstrate significant potential as diagnostic biomarkers for AMI.
• These biomarkers may aid in distinguishing AMI from stable CAD and reflect endothelial dysfunction.
• Further investigation into their role in regulating endothelial dysfunction in AMI is warranted.